References
- Boulet LP, Reddel HK, Brightling C, Brusselle G. GINA fosters World Asthma Day 2020 to prevent asthma deaths. Am J Physiol Lung Cell Mol Physiol 2020;318:L998–L1000. doi:https://doi.org/10.1152/ajplung.00075.2020.
- Serebrisky D, Wiznia A. Pediatric asthma: a global epidemic. Ann Glob Health. 2019;85:6. doi:https://doi.org/10.5334/aogh.2416.
- Nordon C, Grimaldi-Bensouda L, Pribil C, Nachbaur G, Amzal B, Thabut G, Marthan R, Aubier M. Clinical and economic burden of severe asthma: a French cohort study. Respir Med. 2018;144:42–49. doi:https://doi.org/10.1016/j.rmed.2018.10.002.
- Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N, Emoto K, Tohda Y. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69(1):53–60. doi:https://doi.org/10.1016/j.alit.2019.06.003.
- Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med. 2012;6:27–40. doi:https://doi.org/10.4137/CCRPM.S7793.
- Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012;49(2):144–152. doi:https://doi.org/10.3109/02770903.2011.648296.
- Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C, Devouassoux G, de Blay F, Couderc LJ, Didier A, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–419. doi:https://doi.org/10.1378/chest.12-1961.
- Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. doi:https://doi.org/10.1002/14651858.CD003559.pub4.
- Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M, Zhong N. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study. Allergy Asthma Immunol Res. 2016;8(4):319–328. doi:https://doi.org/10.4168/aair.2016.8.4.319.
- Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–1216. doi:https://doi.org/10.1016/j.jaci.2009.09.021.
- Kulus M, Hebert J, Garcia E, Fowler TA, Fernandez VC, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010;26(6):1285–1293. doi:https://doi.org/10.1185/03007991003771338.
- Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015. doi:https://doi.org/10.1056/NEJMoa1009705.
- Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36. doi:https://doi.org/10.1542/peds.108.2.e36.
- Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:https://doi.org/10.1183/09031936.00202013.
- Folque MM, Lozano J, Riggioni C, Piquer M, Alvaro M, Machinena A, Giner MT, Dominguez O, Jimenez-Feijoo RM, Dias DCM, et al. Real-life’ experience in asthmatic children treated with omalizumab up to six-years follow-up. Allergol Immunopathol (Madr). 2019;47(4):336–341. doi:https://doi.org/10.1016/j.aller.2018.09.009.
- Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26(6):551–556. doi:https://doi.org/10.1111/pai.12405.
- Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol. 2009;123(1):107–113. doi:https://doi.org/10.1016/j.jaci.2008.09.050.
- Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling ZJJ, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:https://doi.org/10.2147/JAA.S176026.
- Janjua S, Schmidt S, Ferrer M, Cates CJ. Inhaled steroids with and without regular formoterol for asthma: Serious adverse events. Cochrane Database Syst Rev. 2019;9:CD6924. doi:https://doi.org/10.1002/14651858.CD006924.pub4.
- Heffler E, Bagnasco D, Canonica GW. Strategies to reduce corticosteroid-related adverse events in asthma. Curr Opin Allergy Clin Immunol. 2019;19(1):61–67. doi:https://doi.org/10.1097/ACI.0000000000000493.
- Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics. 2008;122(1):e53–e61. doi:https://doi.org/10.1542/peds.2007-3381.
- Briars LA, Diaz A. Omalizumab: a steroid-sparing option for improving pediatric asthma management? J Pediatr Health Care. 2005;19(6):386–391. doi:https://doi.org/10.1016/j.pedhc.2005.09.001.
- Rees PJ. Review: omalizumab reduces exacerbation and steroid use in chronic asthma. Arch Dis Child Educ Pract Ed. 2007;92(4):ep127. doi:https://doi.org/10.1136/ebm.12.1.11.